AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02531334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: TA-65
Description: 2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
Study NCT02531334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: 2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
Study NCT02554188 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Seasonal influenza (flu) vaccine
Description: Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older
Study NCT04404283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: 1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks
Study NCT04404283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
Study NCT04404283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
Study NCT04404283 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: 20 mg given by mouth (orally) daily
Study NCT04404283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20 mg given by mouth (orally) daily
Study NCT04404283 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous infusion every 3 weeks
Study NCT01722734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text message reminders
Description: Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
Study NCT01682720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Study NCT01682720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01682720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match SOF
Description: Placebo to match SOF administered orally once daily
Study NCT01682720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match RBV
Description: Placebo to match RBV administered orally in a divided daily dose
Study NCT03989687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fuji Triage
Description: glass ionomer sealant
Study NCT03989687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolation
Description: rubber dam or cotton roll isolation
Study NCT00863629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
Study NCT00863629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell \<180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
Study NCT05805540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active recovery
Description: Subjects was carried out using a bicycle ergometer. The subjects pedaled for 25 minutes at 50% of the maximum heart rate (HRmax)
Study NCT05805540 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects drank a water-based drink and sweetener. Subject sat for 25 minutes until all recovery methods were completed.
Study NCT02617420 — intervention group
Intervention type: DEVICE
Intervention: Propeller Health Monitoring Device
Study NCT02430636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
Study NCT02430636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT03274310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational text messages
Description: Educational text message about ways to decrease household transmission of influenza and other respiratory infections
Study NCT04025372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
Study NCT04025372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Description: In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
Study NCT04025372 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
Study NCT04025372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
Study NCT03414970 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03414970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03414970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated RT
Study NCT04625855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBPM-PI-HBr
Description: TBPM-PI-HBr (3 x 200 mg tablets) once
Study NCT03473743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive erdafitinib orally.
Study NCT03473743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab
Description: Participants will receive cetrelimab by intravenous infusion.
Study NCT03473743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
Study NCT03473743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
Study NCT04319094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEERS
Description: Peer mentors deliver depression care that include social support and coping skills, focused on goal setting and small behavioral changes.
Study NCT04319094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social interaction
Description: Study staff will provide a combination of 8 social interaction visits and phone calls to the participants randomized to this condition.
Study NCT01016483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Study NCT03930810 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical biliary diversion
Description: Surgical interruption of enterohepatic circulation
Study NCT03497117 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lung Clearance Index
Description: To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
Study NCT02155582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: 0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
Study NCT01016483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study NCT03497117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MRI with PFP
Description: * Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.
Study NCT01016483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01016483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00038194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT00038194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT03964012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NmCV-5
Description: Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W\&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A\&X conjugated to tetanus toxoid and C,Y\&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
Study NCT03964012 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y\&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
Study NCT04632329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Treatment via the Mercury Multi-Pressure Dial
Description: Negative Pressure Treatment via the Mercury Multi-Pressure Dial
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: Test fluoride toothpaste and test fluoride mouth rinse
Study NCT02554188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal influenza (flu) vaccine
Description: Seasonal influenza (flu) vaccine~* Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~* Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older
Study NCT02554188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: A 5-day low calorie fasting-mimicking diet
Study NCT03080974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
Study NCT03080974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Description: Non-thermal ablation of tumor
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Test fluoride toothpaste and test fluoride mouth rinse
Study NCT02186132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.6 mg
Description: Atropine 0.6 mg intravenous
Study NCT02186132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 1.2 mg
Description: Atropine 1.2 mg intravenous
Study NCT03676985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 5mg/kg
Description: 5mg/kg/times bi-week IV administration of ZKAB001
Study NCT03676985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 10mg/kg
Description: 10mg/kg/times bi-week IV administration of ZKAB001
Study NCT03676985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 15mg/kg
Description: 15mg/kg/times bi-week IV administration of ZKAB001
Study NCT01163032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20 mg tasimelteon capsules, PO daily for 6 months
Study NCT01163032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, PO daily for 6 months
Study NCT04159961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ211
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous
Study NCT02192086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: goal directed fluid therapy
Description: The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe.
Study NCT02192086 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg \* wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values).
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monoflurophosphate
Description: United Kingdom marketed fluoride toothpaste
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water rinse
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile water
Description: Sterile water rinse
Study NCT01128972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile water
Description: Sterile water rinse
Study NCT03760380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 1 - Neutral
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
Study NCT03760380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 1 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
Study NCT03760380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 2 - Neutral
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
Study NCT03760380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sole 2 - Offset
Description: Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
Study NCT01786746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy. 12 sessions.
Study NCT03884348 — intervention group
Intervention type: DRUG
Intervention: proton pump inhibitor, amoxicillin, clarithromycin
Description: non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
Study NCT03884348 — intervention group
Intervention type: DRUG
Intervention: proton pump inhibitor, amoxicillin, metronidazole
Description: clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
Study NCT03677960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968 cream
Description: Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
Study NCT00736190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet (marketed formulation) taken orally once daily
Study NCT03504020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Belt Research System
Description: The ECG Belt Research System is used to identify the best vector and programming parameters.
Study NCT03065751 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmaexchange
Description: TPE against fresh frozen plasma
Study NCT03704103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iSage
Description: The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.